27 results
8-K
EX-2.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-2.3
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-2.4
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-2.2
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
10-Q
2020 Q3
EX-2.5
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
Quarterly report
6 Nov 20
4:11pm
8-K
EX-2.1
9ud vm13ap3a09he8q9x
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
SC TO-C
EX-2.1
9u58wkf
10 Aug 20
Information about tender offer
9:50pm
8-K
EX-2.1
g8usf89ly5eh12 15m
10 Aug 20
Tender and Support Agreement
9:48pm
8-K
EX-2.1
r7x 9o7smred
5 Mar 19
Entry into a Material Definitive Agreement
5:16pm
8-K
EX-2.1
h8i0fddoruce 7ct1
9 Aug 18
Entry into a Material Definitive Agreement
9:05am
8-K
EX-2.1
b67zkefedy
4 Oct 17
Entry into a Material Definitive Agreement
12:00am
8-K/A
EX-2.1
rk8jv 2s1yy
22 Mar 16
Financial Statements and Exhibits
12:00am
8-K
EX-2.1
yutd85iklba7ncc mz6
18 Dec 15
Ligand to Acquire OMT, Inc., a Leader in Human Antibody Generation, for $178 Million in Cash and Stock
12:00am
8-K
EX-2.1
pceuyg
26 Jan 11
Entry into a Material Definitive Agreement
12:00am
8-K
EX-2.1
p4ii7btqtiher opt6g
28 Jan 10
Entry into a Material Definitive Agreement
12:00am
8-K
EX-2.1
4z6la6rhgkp ia8kkoj
24 Dec 09
Ligand Completes Neurogen Acquisition
12:00am
425
EX-2.1
v75tv
26 Sep 08
Business combination disclosure
12:00am
8-K
EX-2.1
bcr uin35
26 Sep 08
Entry into a Material Definitive Agreement
12:00am
425
EX-2.1
fa08 yo26f371hc05h9
25 Sep 08
Business combination disclosure
12:00am